Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL122956 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28763342 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3965533 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7118713 | 0.94 | THRB (0.36) | — | |
| Hydrochloric Acid SCHEMBL30639428 | 0.94 | THRB (0.36) | — | |
| Hydrochloric Acid SCHEMBL28181204 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL9798273 | 0.94 | THRB (0.36) | — | |
| SCHEMBL5547 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL4736873 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL338818 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515647-A | Crystal of quinoline derivative and process for producing the same | 正大天晴药业集团股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-110292580-A | The method for being used to prepare anticancer agent AL3818, its crystal form and its salt | 杭州爱德程医药科技有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-103664890-B | The crystallization of quinoline and preparation method | 正大天晴药业集团股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-103664892-A | Crystal of quinoline derivative | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-103664890-A | Crystal of quinoline derivative and preparation method of crystal | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-102344438-B | Crystal of quinoline derivative and process for producing the same | JIANGSU CHIA TAI TIANQING PHAR | 2014-02-19 | — | — | CN | claimed |
| CN-102344438-A | Crystal of quinoline derivative and process for producing the same | JIANGSU CHIA TAI TIANQING PHAR | 2012-02-08 | — | — | CN | claimed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | claimed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | claimed |
| WO-2025074305-A1 | N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-10 | — | — | WO | disclosed |
| CN-118515647-A | Crystal of quinoline derivative and process for producing the same | 正大天晴药业集团股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-115487187-B | Quinoline derivative for treating gastric cancer | 正大天晴药业集团股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115624550-B | Quinoline derivative for treating gastric cancer | 正大天晴药业集团股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117164465-A | Phenyl cyclopropylamine compound and preparation method and application thereof | 郑州大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-101374814-A | Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
| CN-101309918-A | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
| CN-1903843-A | New polysubstituted 1,1-pyridyloxycyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-31 | — | — | CN | disclosed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | disclosed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | disclosed |